Oxford BioMedica PLC Reports Encouraging Preclinical Data With Retinostat® In Retinopathy And Demonstrates The Potential Of Lentivector® In Other Ocular Diseases

Oxford BioMedica (LSE: OXB), the leading gene therapy company, and its collaborators at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, are presenting three posters at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which is being held from 30 April to 4 May 2006 in Fort Lauderdale, Florida, USA. These posters describe positive preclinical results of RetinoStat in wet age-related macular degeneration and the potential application of the LentiVector system in corneal endothelial disorders.

MORE ON THIS TOPIC